PegBio

PegBio Co., Ltd., founded in 2008, is a biotechnology company dedicated to the independent research and development of innovative therapies for chronic diseases, with a primary focus on endocrine and metabolic disorders. PegBio addresses unmet clinical treatment needs in the field of chronic diseases by utilizing its proprietary HECTORTM technology platform to design and screen innovative molecular entities with "new targets, new sites, and new mechanisms," creating a complementary and multi-benefit product pipeline. Relying on an efficient and experienced research and development team, PegBio has independently developed a series of competitive products, including peptide drugs, protein drugs, and small molecule drugs. PegBio has established a broad R&D pipeline centered on metabolic diseases, covering various chronic conditions. The company has independently developed one core product and five other products in its pipeline to seize significant market opportunities in common chronic and metabolic diseases such as Type 2 Diabetes Mellitus (T2DM), obesity, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Opioid-Induced Constipation (OIC), and congenital hyperinsulinism.